Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:octadecan-1-ol
go back to main search page
Accession:CHEBI:32154 term browser browse the term
Definition:A long-chain primary fatty alcohol consisting of a hydroxy function at C-1 of an unbranched saturated chain of 18 carbon atoms.
Synonyms:related_synonym: 1-hydroxyoctadecane;   1-octadecanol;   Formula=C18H38O;   InChI=1S/C18H38O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h19H,2-18H2,1H3;   InChIKey=GLDOVTGHNKAZLK-UHFFFAOYSA-N;   SMILES=C(CCCCCCCCC)CCCCCCCCO;   Stearylalkohol;   n-1-octadecanol;   n-octadecanol;   n-octadecyl alcohol;   octadecanol;   stearyl alcohol
 xref: Beilstein:1362907;   CAS:112-92-5;   HMDB:HMDB0002350;   KEGG:D01924;   KNApSAcK:C00029422;   LIPID_MAPS_instance:LMFA05000085;   MetaCyc:CPD-7873;   PMID:10884288;   PMID:11722503;   PMID:1583866;   PMID:21137365;   PMID:2241202;   PMID:23173706;   PMID:2666627;   PMID:26673629;   PMID:8373640;   Reaxys:1362907;   Wikipedia:Stearyl_alcohol


show annotations for term's descendants           Sort by:
 
perifosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO [perifosine co-treated with Butyrates] results in increased secretion of AIFM1 protein; [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [perifosine co-treated with vorinostat] results in increased secretion of AIFM1 protein CTD PMID:15781658 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
ISO [perifosine co-treated with Butyrates] results in decreased activity of AKT1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; [perifosine co-treated with Vorinostat] results in decreased activity of AKT1 protein; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Butyrates]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Vorinostat]; perifosine inhibits the reaction [cyadox results in increased phosphorylation of AKT1 protein]
perifosine results in decreased phosphorylation of AKT1 protein
[perifosine co-treated with temsirolimus] results in decreased activity of AKT1 protein
CTD PMID:15781658, PMID:21267448, PMID:30265530, PMID:31445927 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO [perifosine co-treated with Butyrates] results in decreased expression of BAK1 protein; [perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein; [perifosine co-treated with vorinostat] results in decreased expression of BAK1 protein CTD PMID:15781658 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [perifosine co-treated with Butyrates] results in increased activity of BAX protein; [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; [perifosine co-treated with vorinostat] results in increased activity of BAX protein CTD PMID:15781658 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Casp3 caspase 3 multiple interactions
decreases expression
ISO [perifosine co-treated with Butyrates] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP3 protein
perifosine results in decreased expression of CASP3 protein
CTD PMID:15781658, PMID:25416439 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [perifosine co-treated with Butyrates] results in increased activity of CASP8 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP8 protein CTD PMID:15781658 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [perifosine co-treated with Butyrates] affects the localization of CYCS protein; [perifosine co-treated with trichostatin A] affects the localization of CYCS protein; [perifosine co-treated with vorinostat] affects the localization of CYCS protein CTD PMID:15781658 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Egf epidermal growth factor multiple interactions ISO perifosine inhibits the reaction [cyadox results in increased expression of EGF]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of EGF] CTD PMID:30265530 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Fas Fas cell surface death receptor affects response to substance ISO perifosine affects the susceptibility to FAS protein CTD PMID:31445927 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [perifosine co-treated with cyadox] results in increased expression of FOXO1 mRNA; [perifosine co-treated with Hydrogen Peroxide] results in increased expression of FOXO1 mRNA CTD PMID:30265530 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Lat2 linker for activation of T cells family, member 2 multiple interactions
decreases expression
decreases response to substance
ISO ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]
LAT2 protein results in decreased susceptibility to perifosine
CTD PMID:23001822 NCBI chr12:25,114,099...25,128,381
Ensembl chr12:25,119,355...25,125,749
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat] CTD PMID:15781658 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [perifosine co-treated with Butyrates] results in decreased activity of MAPK1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK1 protein CTD PMID:15781658 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [perifosine co-treated with Butyrates] results in decreased activity of MAPK3 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK3 protein CTD PMID:15781658 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO [perifosine co-treated with Butyrates] results in increased activity of MAPK8 protein; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; [perifosine co-treated with vorinostat] results in increased activity of MAPK8 protein CTD PMID:15781658 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [perifosine co-treated with temsirolimus] results in decreased activity of MTOR protein CTD PMID:21267448 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Tnf tumor necrosis factor increases response to substance ISO perifosine results in increased susceptibility to TNF protein CTD PMID:31445927 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA]; perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA] CTD PMID:30265530 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19787
    role 19734
      biological role 19734
        biochemical role 19282
          metabolite 19263
            eukaryotic metabolite 18908
              plant metabolite 17360
                octadecan-1-ol 18
                  16-methyloctadecan-1-ol 0
                  allyl octadecyl oxalate 0
                  perifosine 18
                  stearyl oleate 0
                  stearyl palmitate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19787
    subatomic particle 19784
      composite particle 19784
        hadron 19784
          baryon 19784
            nucleon 19784
              atomic nucleus 19784
                atom 19784
                  main group element atom 19672
                    main group molecular entity 19672
                      s-block molecular entity 19430
                        hydrogen molecular entity 19420
                          hydrides 18686
                            organic hydride 18249
                              organic fundamental parent 18249
                                hydrocarbon 17969
                                  alkane 13684
                                    long-chain alkane 415
                                      octadecane 60
                                        octadecan-1-ol 18
                                          16-methyloctadecan-1-ol 0
                                          allyl octadecyl oxalate 0
                                          perifosine 18
                                          stearyl oleate 0
                                          stearyl palmitate 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.